WallStSmart

Abbott Laboratories (ABT)vsBoston Scientific Corp (BSX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 129% more annual revenue ($48.23B vs $21.07B). BSX leads profitability with a 16.6% profit margin vs 9.8%. BSX appears more attractively valued with a PEG of 0.63. BSX earns a higher WallStSmart Score of 62/100 (C+).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

BSX

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-38.8%)

Margin of Safety

-38.8%

Fair Value

$76.51

Current Price

$109.41

$32.90 premium

UndervaluedFair: $76.51Overvalued
BSXOvervalued (-7.2%)

Margin of Safety

-7.2%

Fair Value

$39.17

Current Price

$43.50

$4.33 premium

UndervaluedFair: $39.17Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$184.98B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$60.84B9/10

Large-cap with strong market position

PEG RatioValuation
0.638/10

Growing faster than its price suggests

P/E RatioValuation
17.7x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.2%8/10

Strong operational efficiency at 20.2%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
39.5x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-43.7%2/10

Earnings declined 43.7%

BSX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

EPS GrowthGrowth
-21.5%2/10

Earnings declined 21.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 14.5% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : BSX

The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.

Key Dynamics to Monitor

ABT carries more volatility with a beta of 0.58 — expect wider price swings.

ABT is growing revenue faster at 14.5% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (62/100 vs 52/100), backed by strong 16.6% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?